Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
posted on
Feb 11, 2022 08:52AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
"fair value to shareholders would be an outright sale of the company."
I agree, but how do you get around the ongoing clinical trials with Pfizer and Newsoara plus other partnership interests that presently exist?
https://www.zenithepigenetics.com/programs/business-strategy
Koo